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Abstract Metformin, a generic glucose lowering drug,
inhibits cancer growth expressly in models that employ
high fat/cholesterol intake and/or low glucose availability.
Here we use a targeted tracer fate association study
(TTFAS) to investigate how cholesterol and metformin
administration regulates glucose-derived intermediary
metabolism and macromolecule synthesis in pancreatic
cancer cells. Wild type K-ras BxPC-3 and HOM:
GGT(Gly) ? TGT(Cys) K12 transformed MIA PaCa-2
adenocarcinoma cells were cultured in the presence of
[1,2-13C2]-D-glucose as the single tracer for 24 h and
treated with either 100 lM metformin (MET), 1 mM
cholesteryl hemisuccinate (CHS), or the dose matching
combination of MET and CHS (CHS–MET). Wild type
K-ras cells used 11.43 % (SD = ±0.32) of new acetyl-
CoA for palmitate synthesis that was derived from glucose,
while K-ras mutated MIA PaCa-2 cells shuttled less than
half as much, 5.47 % [SD = ±0.28 (P \ 0.01)] of this
precursor towards FAS. Cholesterol treatment almost
doubled glucose-derived acetyl-CoA enrichment to 9.54 %
(SD = ±0.24) and elevated the fraction of new palmitate
synthesis by over 2.5-fold in MIA PaCa-2 cells; whereby
100 lM MET treatment resulted in a 28 % inhibitory
effect on FAS. Therefore, acetyl-CoA shuttling towards its
carboxylase, from thiolase, produces contextual synthetic
inhibition by metformin of new palmitate production.
Thereby, metformin, mutated K-ras and high cholesterol
each contributes to limit new fatty acid and potentially cell
membrane synthesis, demonstrating a previously unknown
mechanism for inhibiting cancer growth during the meta-
bolic syndrome.
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1 Introduction
Metformin (1,1-dimethylbiguanide) is the first-line oral
therapy prescribed for type 2 diabetes (Viollet et al. 2012).
It is a potent anti-hyperglycemic and insulin-sensitizing
drug that works by decreasing hepatic gluconeogenesis,
activating insulin receptor tyrosine phosphorylation (Viol-
let et al. 2012), decreasing intestinal glucose absorption,
and increasing skeletal muscle and adipose tissue glucose
uptake (del Barco et al. 2011). Moreover, metformin
increases the more active mitochondria-bound hexokinase
and actin-bound phosphofructokinase in streptozotocin-
induced diabetic male Swiss mice hearts, enhancing glu-
cose sensitivity of those organs (da Silva et al. 2012).
Interestingly, numerous studies have reported a lower
risk of cancer (Evans et al. 2005; Monami et al. 2011;
Ruiter et al. 2012; Libby et al. 2009) and a reduced risk of
cancer-related mortality in diabetics (Bo et al. 2011;
Bowker et al. 2006) treated with metformin compared to
diabetics that were prescribed other glucose-lowering
therapies. Recently, improved survival was observed in
diabetic pancreatic cancer patients who were taking met-
formin (Sadeghi et al. 2012). Published treatment protocols
suggest that lactic acidosis is potentially a very serious
(Fitzgerald et al. 2009) but a rare side effect of metformin,
although the link with metformin has been questioned
(Preiss and Sattar 2009).
Various mechanisms of action for metformin’s anti-cancer
properties have been published, such as its ability to inhibit the
mammalian target of rapamycin complex I (mTORC1) in an
AMP activated protein kinase (AMPK)-mediated manner
(Mihaylova and Shaw 2011). Other reported mechanisms are
the AMPK-independent suppression of mTORC1 activation
via inhibition of the Regulator complex (Kalender et al. 2010;
Sancak et al. 2008, 2010) and the up regulation of the
mTORC1 inhibitor REDD1 (regulated in development and
DNA damage responses) (Ben Sahra et al. 2011). Metformin
has also been shown to prevent insulin/IGF1 crosstalk with G
protein coupled receptor (GPCR) signaling (Kisfalvi et al.
2009) and to induce p53-dependent cell cycle arrest and
apoptosis (Ben Sahra et al. 2010b).
Metabolic downstream targets of metformin involve the
electron transport chain (ETC) complex I (Whitaker-
Menezes et al. 2011; Gonzalez-Barroso et al. 2012; Dykens
et al. 2008), which results in energy depletion in cancer
cells. The addition of metformin with 2DG induces cell
death and promotes ATP depletion, underscoring the
importance of oxidative phosphorylation as a cancer ther-
apeutic target (Cheong et al. 2011). In addition, it is
demonstrated that metformin inhibits glycolytic flux by
suppressing the translocation of glucokinase from the
nucleus into cytosol in rat hepatocytes, possibly due to its
ATP-depleting properties (Guigas et al. 2006).
In vivo, metformin decreases the expression of acetyl
CoA carboxylase, fatty acid synthase and citrate lyase,
which are involved in hepatic fatty acid synthesis (Bhalla
et al. 2012; Algire et al. 2010). Kim et al. (2011) demon-
strated that metformin hinders the AMPK-dependent
transactivation of nuclear receptor TR4, which then fails to
bind to TR4RE on the SCD1 50 promoter for impairing
SCD1 gene expression. This results in the inhibition of
lipogenesis and up regulation of b-oxidation in hepatocytes
(Kim et al. 2011).
Metabolic adaptation of transformed mammalian cells to
codon K12K-ras mutation is identical in fibroblasts (Vizan
et al. 2005) and MIA PaCa-2 cells, the latter harboring the
GGT ? TGT mutation (Lopez-Crapez et al. 1997). The
mutant phenotype exhibits greatly increased glycolysis
with a low flux along pathways that produce lipid synthesis
precursors via the oxidative branch of the pentose cycle,
pyruvate dehydrogenase and citrate synthase. The K-ras
oncogene also mediates a metabolic phenotype that readily
trades glucose-derived acetyl-CoA between cholesterol
synthesis, controlled by biosynthetic thiolases, and the fatty
acid synthase precursor malonyl-CoA, controlled by
acetyl-CoA carboxylase. In the presence of either synthetic
(C75) or natural (luteolin) FAS inhibitors, cholesterol
synthesis readily serves as the alternate route for glucose-
derived acetyl-CoA use in MIA PaCa-2 cells (Harris et al.
2012). This channeling of acetyl-CoA between palmitate
and cholesterol syntheses serves as the marker of drug
efficacies inhibiting metabolic enzymes that compete for
the glucose-derived acetyl-CoA substrate.
In the present study we evaluated the metabolic effects
of a physiologically relevant dosage of metformin on two
pancreatic cancer cell lines. We show metformin, in the
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context of available acetyl-CoA and cholesterol, limits
fatty acid synthesis in pancreatic tumor cells with mutated
K-ras. This explains how metformin controls K-ras
induced malignant cell growth via limiting new fatty acid
production necessary for cancer cell formation in patients
with insulin resistance and the metabolic syndrome. The
results of our report provide metabolic explanations for
studies showing an anti-cancer effect of metformin in
animals fed with a high energy (39.8 % lard) diet (Algire
et al. 2008, 2010).
2 Materials and methods
2.1 Cell culture and proliferation
BxPC-3 and MIA PaCa-2 pancreatic cancer cells were
purchased from American Type Culture Collection
(Manassas, VA, USA). Cell culture media, penicillin–
streptomycin (P/S) and trypsin–EDTA were purchased
from Mediatech (Manassas, VA, USA). BxPC-3 cells were
cultured in RPMI media and MIA PaCa-2 cells were grown
in DMEM. Both media were supplemented with 10 % FBS
from PAA Laboratories, Inc., (Pasching, Austria) and 1 %
P/S. The cells were incubated at 37 C, 5 % CO2 and 95 %
humidity and passaged with 0.25 % trypsin–EDTA once
the cells reached 75–80 % confluence. Cells treated with
cholesteryl hemisuccinate (CHS; Sigma-Aldrich, St. Louis,
MO), from now on referred to as BxPC3-CHS and MIA
PaCa-2-CHS, were incubated in media supplemented with
1 mM CHS complexed to 1 % BSA for 2 weeks prior to
metabolomics analysis. The 1 mM cholesteryl hemisucci-
nate (CHS) dose was used because when compared BxPC-
3 (no CHS) versus BxPC-3 (pre-treated with CHS sup-
plementation in the media for 2 weeks) we observed, via
western blot, that the CHS-treated cells were more resistant
to the AKT inhibitor PH-427, which indicates in vitro
biological activity in K-ras negative cells.
Cell proliferation was assessed by plating 1 9 105 cells
into T-25 cm2 flasks. Cells were immediately treated with
100 lM metformin for 72 h as appropriate. The doubling
times of BxPC-3 cells and MIA PaCa-2 are 48–60 and
40 h, respectively (Deer et al. 2010). Based on these
reported doubling times, we decided to use 72 h for cell
proliferation measurements to ensure that the cells have
undergone one round of doubling before counting. Cells
were then counted using trypan blue exclusion.
2.1.1 MTT assay
BxPC-3 and MIA PaCa-2 cells were plated at 2,000 and
500 cells, respectively in 96-well plates and incubated for
24 h in complete RPMI or DMEM media (?1 mM CHS).
The following day (day 1), cells were treated with either
vehicle (PBS) or 100 lM metformin and incubated for
4 days. On day 5, 50 lL of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) was added to the
wells. After 4 h of incubation, the resulting precipitates
were dissolved in 100 lL DMSO. Plates were read at
540 nm using the Synergy 2 Microplate Reader.
2.2 Stable glucose isotope
All reagents were purchased from Sigma-Aldrich (St. Louis,
MO) unless otherwise stated. All experiments were con-
ducted in triplicate. Twenty-four hours prior to metformin
treatment and metabolomics study, 2 9 106 cells were
grown in T-75 cm2 culture flasks with glucose and sodium
pyruvate-free RPMI and DMEM containing 10 % FBS, 1 %
P/S, 4.5 g glucose/L, of which 23–40 % of total final glucose
was derived from the [1,2-13C]-D-glucose tracer (Isotec,
Miamisburg, OH, USA) after media preparation, as mea-
sured by GC–MS and reported in Table 1. The tracer was
added to the media for all cells along with 100 lM metfor-
min in half of the non-CHS and CHS-treated cells and
allowed to incubate for 24 h. Media and trypsinized cell
lysates were collected and frozen at -80 C until analysis.
2.3 Product extraction and derivatization
Extraction and derivatization procedures for glucose, cho-
lesterol, fatty acids, lactate, CO2 and glutamate were pre-
viously published (Harrigan et al. 2006; Harris et al. 2012).
Sterols and fatty acids were extracted by saponification of
Trizol (500 lL, Invitrogen, Carlsbad, CA) cell extract after
removal of the upper glycogen- and RNA-containing
supernatant using 30 % KOH and 70 % ethanol (300 lL
each) for 2 h. Sterol extraction was performed using 5 mL
petroleum ether (EMD, Gibbstown, NJ) with repeated
shaking for 20 s three times. The molecular ion of choles-
terol was monitored at the m/z 386 ion cluster. Fatty acids
were extracted by further acidification using 6 N hydro-
chloric acid to pH below 2.0 and repeated vortexing with
5 mL petroleum ether. Fatty acids (palmitate) were moni-
tored at m/z 270 using canola oil as positive control. The
enrichment of acetyl units in media and cell pellet palmitate
in response to CHS and metformin treatments was deter-
mined using the mass isotopomer distribution analysis
(MIDA) approach. Acetyl-CoA and fractions of new syn-
thesis were calculated from the m4/m2 ratio using the for-
mula m4/m2 = (n-1)/2(p/q), where n is the number of
acetyl units, p is the 13C labeled precursor acetate fraction
and q is the 12C labeled natural acetate fraction (p ? q = 1)
(Lee 1996). Additional details of mathematical approaches
are described in by Lee et al. (1992) for spectra processing
and 13C positional distribution diagnostics.
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For glucose extraction, 500 lL each of 0.3 N barium
hydroxide and 0.3 N zinc sulfate were added to 100 lL
media. Samples were vortexed and centrifuged for 15 min
at 10,000 rpm. Supernatant was dried on air over heat and
were derivatized by adding 150 lL hydroxylamine solution
and incubated for 2 h at 100 C followed by addition of
100 lL of acetic anhydride. Samples were incubated at
100 CC for 1 h and dried under nitrogen over heat as
previously described in the fatty acids derivatization sec-
tion. Ethyl acetate (200 lL) was added. Peak glucose ion
was detected at m/z 187 cluster.
Lactate was extracted from media through acidification
of 100 lL media with HCl and addition of 1 mL of ethyl
acetate. The resulting aqueous layer was dried under
nitrogen over heat and derivatized using lactate standard
solution as positive control. Two hundred microlitre of 2,2-
dimethoxypropane was added followed by 50 lL of 0.5 N
methanolic HCl. Samples were incubated at 75 C for an
hour. Sixty microlitre of n-propylamine was added and
samples were heated for 100 C for an hour followed by
addition of 200 lL dichloromethane. Heptafluorobutyric
anhydride (15 lL) was added followed by 150 lL of
dichloromethane and samples were subjected to GC/MS.
M1 and m2 lactate were differentiated to distinguish the
pentose phosphate flux from anaerobic glycolysis (Lee
1996; Lee et al. 1998) and the ion cluster at m/z 328 was
examined.
Media glutamate was converted into its n-trifluoroac-
teyl-n-butyl derivative and monitored at ion clusters at m/
z152 and m/z198.
13CO2 Assay for CO2 was generated by adding equal
volumes (50 lL) of 0.1N NaHCO3 and 1N HCl to spent
media and 12CO2/
13CO2 ion currents were monitored and
calculated from the m/z44 and m/z45 peak intensities,
respectively, using 13CO2/
13CO2 of cell culture cabinet’s
CO2 thank as the reference ratio for
13CO2 D calculations.
2.4 Gas chromatography/mass spectrometry
Agilent 5975 Inert XL Mass Selective Detector connected
to HP6890N Network gas chromatograph was used to
detect mass spectral data under the following settings: GC
inlet 230 C, MS source 230 C, MS Quad 150 C (Harris
et al. 2012). For media CO2, glucose, lactate and glutamate
analyses, an HP-5 column (30 m length 9 250 lm diam-
eter 9 0.25 lm thickness) was used while a DB-23 column
(60 m length, 250 lm diameter 9 0.15 lm thickness) was
used for fatty acid measurement.
2.5 Statistics
Mass spectral analyses were obtained by consecutive and
independent injections of 1 lL sample using an autosampler
with optimal split ratios for column loading (106 [ abun-
dance [ 104 abundance). Data was accepted if the standard
sample deviation was below 10 % of the normalized peak
intensity (integrated peak area of ion currents; 100 %)
among repeated injections. Data download was performed in
triplicate manual peak integrations using modified (back-
ground subtracted) spectra under the overlapping isotopomer
peaks of the total ion chromatogram (TIC) window displayed
by the Chemstation (Agilent, Palo Alto, CA) software. A
two-tailed independent sample t test was used to test for
significance (P \ 0.05, P \ 0.01) between control and
treated groups (*, **) or between cell lines (#).
2.6 Visual system wide association interface
Rapid system-wide association study (SWAS) evaluation
of both cell lines was performed by the color assisted visual
isotopolome data matrix screening tool (Harrigan et al.
2006), to diagnose phenotypic differences and response to
drug treatment.
2.7 Practical note to multiple SWAS entry
interpretations
Please note that there is a distinct functional relevance of
each value in Table 1, which is the source matrix for the
SWAS interface. For example, there are four table entries
for palmitate, which show close to equilibrium non-treat-
ment responsive chain elongation of shorter (C14:0) acyl
chain by a single acetyl unit from glucose to form 13C m2
palmitate (101). On the other hand there are significant
differences in new palmitate synthesis, which results in
altered 13C labeled fractions (98), as well as its synthesis
from scratch (FNS; 102) with varying glucose derived
acetyl-CoA enrichments (103). For System level interpre-
tations we take into account that a significant inhibitory
effect of metformin in net new palmitate synthesis from
glucose may be considered more rate limiting on new
membrane synthesis and cell proliferation, while its effect
on elongating a previously existing shorter acyl chain is not
affected. Therefore, multiple SWAS interface entries for the
same product clarify the potential biological impact(s) of
MET treatment on important precursor-product relation-
ships in a complex biological system.
3 Results
3.1 Cell viability
The ability of metformin (MET, 100 lM) to affect cell
viability of various PDAC cell lines with and without CHS
pre-treatment for 2 weeks was examined using MTT assay
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(Fig. 1a). Metformin alone was unable to decrease cancer
cell viability after 4 days of drug treatment. Hence, the
metabolic impacts of CHS and metformin in this study
cannot be attributed to cell death inducing properties.
3.2 Cell proliferation
The ability of MET to affect cell proliferation for 72 h in
all groups was assessed by counting using the trypan blue
exclusion method. MET treatment did not significantly
alter cell proliferation in control or CHS-treated cells
(Fig. 1b). As expected, MIA PaCa-2 cells showed shorter
doubling times than BxPC-3 cells did.
3.3 Heavy [1,2-13C2]-D-glucose enrichment
and cholesteryl hemisuccinate (CHS) media
preparation
There is a uniform decrease in 13C-glucose labeled fraction
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Fig. 1 a Cell survival of various pancreatic adenocarcinoma cell
lines treated with metformin. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay was performed to measure cell
viability in BxPC-3 and MIA PaCa-2 cells after treatment with
metformin (100 lM, MET) in the absence or presence of cholesteryl
hemisuccinate (CHS) pre-treatment for 2 weeks. Dark bars are
control and light bars are MET-treated cells. All data are mean ± SD
(n = 3 per group). b Cell proliferation of various pancreatic
adenocarcinoma cell lines treated with metformin. Cell proliferation
was assessed by plating 1 9 105 cells into T-25 cm2 flasks in
triplicate. Cells were immediately treated with 100 lM metformin for
72 h as appropriate. Cells were then counted using trypan blue
exclusion. We used a relatively short (72 h) incubation time for MET
treatment, which showed a slowing trend in MIA proliferation with no
(yet) significant differences but decreasing NS P values [Fig. 1b;
(P = 0.293-MET; 0.139-CHS; 0.089-CHS ? MET)]. BxPC-3 cells
fell short of showing initial response to MET (P = 0.425-MET;
0.118-CHS; 0.127-CHS ? MET)
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[1,2-13C2]-D-glucose of non-CHS-treated BxPC-3 and MIA
PaCa-2 cells in comparison with their cell-specific controls
(Fig. 2—EZTopolome (K-ras) ID 280 and 283; Table 1,
media 13C glucose panel 280 and 283). This difference is
consistent with the increased natural 13C labeled glucose
ratio of the excess media that was replaced with CHS in
bovine albumin for CHS treatment. Instead of providing
calculated values, we report, as determined by GC–MS,
exact [1,2-13C2]-D-glucose enrichment after preparing all
FBS, albumin and CHS supplemented DMEM and RPMI
in Table 1. More specifically, there were a relative 18.8
(±0.15) and 29.4 % (±0.01 %) differences in CHS solu-
tion treated RPMI (BxPC-3) and DMEM (MIA PaCa-2) in
[1,2-13C2]-D-glucose enrichment (please note that glucose
consumption between cell lines and among treatments
remains unaffected), which are shown in Fig. 2—
EZTopolome(K-ras) ID 6 and 7; Table 1, media glucose
panel 6 and 7, before and after the 24-h culturing period.
Due to the expected and observed differences in [1,2-13C2]-
D-glucose in the CHS containing media, below we report
either 13C isotope ratios in glucose-derived isotopomer
products as positional 13C enrichment (mn/mk) or divide
isotopomer extracted ion chromatogram (EIC) by the 13C
labeled fraction (mn/Rm). These isotopomer markers of
glucose to product flux show [1,2-13C2]-D-glucose tracer
distribution and thus readily reflect changes in cells’ phe-
notypes after MET treatment. In other words, normalized
isotopomer distribution patterns are independent of the
amount of tracer uptake, while product concentrations are
reported as total ion currents that include unlabeled and
labeled fractions, alike. In simple words mn/Rm reflects
how cells use a single glucose molecule as surrogate
Fig. 2 EZTopolome(K-ras); isotopolome-wide association study
(IWAS) array showing heat map [percent changes to untreated
control (100 %)] of flux responses associated with CHS and MET
treatment in BxPC-3 and the mutant K-ras (MIA PaCa-2) PDAC cell
lines. EZTopolome(K-ras) contains group averages from Table 1 as
percent of control values in an identical, coherent matrix format
[please note control 100 % values are omitted for EZTopolome (K-
ras)]. Visual system-wide association study (SWAS) evaluations
show the significant phenotypic differences as well as effects of CHS
and MET for a rapid overview of Results. *P \ 0.05 versus control;
**P \ 0.01 versus control; P \ 0.05 versus BxPC-3 (treatment
matching comparison between cell lines)
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markers of flux. This is consistent with the use of
[1,2-13C2]-D-glucose as a true tracer for investigating
metformin’s effect on cultured tumor cell metabolism and
its branching routes. To this end, for example, the identical
*97 % media glucose labeled specifically on the 1,2
carbon positions of the 13C glucose fraction (m2/Rm) indi-
cates that there was truly negligible glucose release by
cultured cells via gluconeogenesis, necrosis and glucose
production to scramble the glucose tracer (Fig. 2—EZTo-
polome(K-ras) ID 283; Table 1, media 13C glucose panel
283; please note the small SD values characteristic of the
mn/Rm mathematics in isotopomer analysis methods).
3.4 Complete glucose oxidation
The decrease in complete glucose oxidation (Fig. 3) into
13CO2 observed in the MIA PaCa-2 cells after the com-
bined CHS and MET treatment indicates that metformin
decreases direct and indirect glucose oxidation relative to
that of amino- and fatty acids (unlabeled substrates) for
ATP synthesis. Thus, K-ras-mutated MIA PaCa-2 cells,
pre-treated with CHS, respond with a decrease in TCA
cycle glucose-derived oxaloacetate and citrate turnover,
anaplerosis and oxidation.
3.5 Lactate synthesis
We observed an expected over 75 % 13C m2 lactate via
glycolysis in the glucose derived (labeled) lactate species
in media (Fig. 2—EZTopolome(K-ras) ID 20 and 22B;
Table 1, media lactate panel 22 and 22B). On the other
hand, 13C m2 glutamate positional labeling, which is a sur-
rogate of pyruvate dehydrogenase activity for pyruvate’s
entry into the TCA cycle, increased in CHS-MET MIA
PaCa-2 cells, supporting metformin’s ability to increase
TCA cycle cataplerosis at the expense of anaplerosis
(anabolic use of pyruvate for new net oxaloacetate and
citrate production, also confirmed with increasing m2/m1)
in this group (Fig. 2—EZTopolome(K-ras) ID 79 and 81;
Table 1, media glutamate panel 79 and 81). Extracellular
glutamate concentration TIC surrogates shown as GC/MS
peak areas decreased in both cell lines after CHS and MET
treatments, which also indicates a uniform decrease in
ketoglutarate and glutamate output of TCA cycle (Fig. 2—
EZTopolome(K-ras) ID 87B; Table 1, media glutamate
panel 87B). While glutamate’s 13C m4 fractions are small
in wild type K-ras BxPC-3 cells (\1 %), there is a prom-
inent 13C m4 glutamate fraction in K-ras mutated MIA
PaCa-2 cells (Table 1, media glutamate panel 81). In MIA
cells CHS and CHS ? MET prominently inhibits oxalo-
acetate’s replenishment from glucose for new citrate syn-
thesis via pyruvate carboxylase and by repeated cycling.
Due to decreased m1 (Table 1, 78) pyruvate carboxylase is
also a potential target of the CHS ? MET treatment.
3.6 Fatty acid palmitate synthesis
Significant phenotypic differences between BxPC-3 and
MIA PaCa-2 cells continue in terms of de novo fatty acid
synthesis deriving from the tracer glucose. There is an
8.95 % (±0.24 %) of glucose-derived palmitate labeled in
BxPC-3 cells, while only 4.61 % (±0.20 %) (*half) in
MIAPaCa-2 (Table 1, pellet palmitate panel 98). This
shows that at baseline, MIA PaCa-2 cells are less lipogenic




































Fig. 3 Complete glucose oxidation of BxPC-3 and MIA PaCa-2
pancreatic adenocarcinoma cells in response to 100 lM metformin
after 24 h of culture with and without CHS pretreatment for 2 weeks.
Treatment with a combination of CHS and metformin in MIA PaCa-2
cells showed a significant inhibition of the TCA cycle measured by a
decrease in glucose oxidation. Control = cells grown in media,
MET = cells treated with metformin (100 lM) for 24 h,
CHS = cells pre-treated with 1 mM CHS for 2 weeks,
CHS ? MET = cells pre-incubated with 1 mM CHS for 2 weeks
then treated with metformin (100 lM) for 24 h. All data are
mean ± SD (n = 3 per group). **P \ 0.01; #P \ 0.05 between cell
lines
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types reach equilibrium in palmitate’s acetyl-CoA enrich-
ment from glucose after 4 h of culturing (data not
shown).
3.7 Sterol ring synthesis
As cholesterol and de novo fatty acid syntheses compete
for acetyl-CoA, external cholesterol (CHS) administration
blocked new sterol synthesis shown by the severely
decreased 13C labeled cholesterol fractions with severely
increased concentrations (total ion current) values
(Table 1, pellet cholesterol panel 235, 236, 238H). How-
ever, in K-ras transformed cells the addition of cholesterol
in the form of CHS increased the glucose derived acetyl-
CoA enrichment and the fraction of newly synthesized
(FNS) palmitate from the tracer glucose derived acetyl-
CoA. Cholesterol supplementation had no effect on BxPC-
30s already high glucose-derived acetyl-CoA enrichment in
palmitate. Hence, addition of CHS did not increase de novo
palmitate synthesis in BxPC-3 cells, yet, there was an up-
regulation, close to double, in glucose-derived synthesis of
new palmitate in CHS-supplemented MIA PaCa-2 cells
(Fig. 2—EZTopolome(K-ras) ID 102, 103; Table 1, pellet
palmitate panel 102, 103). CHS ? MET treatment signif-
icantly decreased de novo palmitate synthesis both BxPC-3
versus control and MIA PaCa-2 versus CHS. This suggests
that metformin clearly is able to inhibit glucose-derived
acetyl-CoA flux via fatty acid synthase in the context of
acetyl-CoA availability and its consumption by acetyl-CoA
carboxylase when sterol synthesis is blocked.
Fig. 4 EZTopolome(CHS-MET); isotopolome-wide association
study (IWAS) array showing heat map [percent changes to CHS
treated control (100 %)] of flux responses associated with MET
treatment in BxPC-3 and the mutant K-ras (MIA PaCa-2) PDAC cell
lines. EZTopolome(CHS-MET) contains group averages from
Table 1 as percent of CHS values in an identical, coherent matrix
format [please note CHS 100 % values are omitted for
EZTopolome(CHS-MET)]. Visual system-wide association study
(SWAS) evaluations show significant phenotypic differences after
CHS treatment, as well as effects of MET for a rapid overview of
Results. (@, P \ 0.05 in comparison with CHS treated control
(100 %); cholesterol 13C content 236 is not shown for comparison due
to low values after external CHS treatment)
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3.8 System wide associations
The rapid system-wide association study (SWAS) evalua-
tion of both cell lines, using the color assisted visual iso-
topolome data matrix screening tool (Harrigan et al. 2006),
confirmed phenotypic differences by increased lactate
production in treated MIA PaCa-2 cells [Fig. 2—EZTo-
polome(K-ras) media 22B; square labeled as 1], the ready
uptake of cholesteryl-hemi succinate by both cell lines
[Fig. 2—EZTopolome(K-ras) pellets 238H; squares labeled
as 2], acetyl-CoA shuttling towards newly synthesized
palmitate [Fig. 2—EZTopolome(K-ras) pellets 102 and
103; squares labeled as 3] in the presence of CHS.
On the other hand, rapid system-wide association study
(SWAS) evaluation of Metformin effect in addition to CHS
treatment (100 %) showed a significant decrease in newly
synthesized palmitate fraction via FAS (m4/m2) [Fig. 4—
EZTopolome(CHS-MET) media 102; square labeled as 4],
the re-labeling of cholesterol in both cell lines [Fig. 4—
EZTopolome(CHS-MET) pellets 235; squares labeled as
5], consistent with less acetyl-CoA used for palmitate
synthesis, as well as further lactate disposal from glucose in
the K-ras positive cells (Fig. 4—EZTopolome(CHS-MET)
pellets 235; squares labeled as 6) in the presence of CHS.
4 Discussions
Various studies have implicated metformin as a potential
anti-cancer agent. However, metformin’s mechanism of
action against cancer remains to be determined (Pollak
2012). Because metformin affects critical metabolic path-
ways to ameliorate diabetic symptoms, and because cancer
cell proliferation is dependent upon altered metabolism, we
investigated how this drug controls metabolic flux in two
PDAC cell lines, BxPC-3 and MIA PaCa-2, using
[1,2-13C2]-D-glucose as the tracer and GC/MS. We used the
stable isotope-labeled dynamic metabolic profiling (SiD-
MAP) (Boros et al. 2003) approach as 13C tracers provide
the most comprehensive means of characterizing cellular
metabolism and uniquely labeled 13C substrates offer
probes of specific reactions within complex networks. The
choice of tracer largely determines the precision available
to estimate metabolic fluxes in complex mammalian sys-
tems, with [1,2-13C2]-D-glucose providing the most precise
estimates for glycolysis, the pentose phosphate pathway,
and the overall metabolic network (Metallo et al. 2009).
In this study, there may be indication that metformin
controls PDAC cell metabolism by inhibiting TCA cycle
anaplerosis and de novo fatty acid palmitate synthesis from
glucose-derived acetyl-CoA. For an overview, please see
Fig. 5. These effects were only observed in MIA PaCa-2
cells that were pre-treated with 1 mM CHS for 2 weeks.
Although previous studies (Meuillet et al. 1999a, b)
implicated that cholesterol supplementation causes a
reduction in plasma membrane fluidity, we herein show
that cholesterol also alters cellular metabolism by redi-
recting glucose-derived acetyl-CoA towards fatty acid
palmitate synthesis, a change through which metformin
gains its contextual efficacy to inhibit FAS, an important
target to control cancer cell proliferation (Little and Kridel
2008; Menendez and Lupu 2007). Metformin may also
control pancreatic cancer cell growth in diabetes and
obesity by limited TCA cycle anaplerosis, an observation
that provides a hypothesis for further testing.
In dose escalating studies 1 mM metformin has been
reported to potentiate the cell proliferation inhibitory effect
of the hexokinase inhibitor 2DG (Sandulache et al. 2011).
At a higher concentration (5 mM), metformin was shown
to cause cell death when combined with 2DG (Cheong
et al. 2011). In the present study, we show that a physio-
logically relevant dosage of metformin (100 lM) (Wiern-
sperger and Rapin 1995) is able to impair glucose
utilization through inhibition of FAS when new cholesterol
synthesis is limited. We raise for the first time that met-
formin may inhibit pyruvate carboxylase flux, indicated by
decreased m1 but increased m2 in glutamate, TCA cycle
output and likely ATP production (not measured) in the
CHS-MIA PaCa-2 cancer cell line. In support of the role of
metformin in ATP depletion, others have published evi-
dence indicating that metformin only and when combined
with 2DG decreases total ATP in human gastric cancer
parenteral p-SK4 (Cheong et al. 2011) and prostate cancer
cells LNCaP (Ben Sahra et al. 2010a, b), compared to their
untreated controls. Previous studies have also implicated
contextual factors that enable metformin’s anti-cancer
properties (Menendez et al. 2012).
Palmitate is the sole product of FAS and its dependence
on acetyl- and malonyl-CoA availabilities is evident; pal-
mitate’s 13C positional labeling from glucose-derived
acetate demonstrates a robust, over twofold increase in
response to CHS. As cellular metabolic reprogramming is
evident after cholesterol pre-treatment in pancreatic cancer
cells, the same may occur in the obese diabetic cancer
patient with increased circulating cholesterol. The presence
of cholesterol establishes the flux-based context in which
efficacies of metformin are high because of tissue speci-
ficities in which FAS gene expression is already high due
to negative feedback (low product concentrations). Such
modalities include pancreatic cancer (Walter et al. 2009).
Interestingly, in primary cultured rat hepatocytes, met-
formin affected neither fatty acid oxidation nor triglyceride
synthesis (Fulgencio et al. 2001), yet in an in vivo model of
colon (Algire et al. 2010) and hepatocellular carcinoma
(HCC) (Bhalla et al. 2012) with circulating cholesterol,
metformin readily decreased FAS expression. In our study
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metformin was effective in altering palmitate synthesis
only after glucose-derived acetyl-CoA was re-directed
towards acetyl-CoA carboxylase from biosynthetic thio-
lase, HMG-CoA and cholesterol synthesis by CHS
administration. This finding suggests that metformin may
inhibit acetyl-CoA carboxylase, which has been suggested
as a cancer promoting enzyme (Wakil and Abu-Elheiga
2009), providing malonyl-CoA precursor directly for FAS.
Determining the cause of the apparent differences in the
effects of metformin between BxPC-3 and MIA PaCa-2
cell lines represents an exciting research endeavor. A
recent study has shown that, in vitro, RAS diffusion is
slowed after cholesterol loading in COS-7 cells (Goodwin
et al. 2005). Given the evidence that mutations in K-ras
show distinct metabolic phenotypes (Vizan et al. 2005), it
is possible that difference in K-ras status between BxPC-3
(WT K-ras) and MIA PaCa-2 (mutated K-ras), besides
apparent differences in the culture media, contribute sig-
nificantly to their diverse response to cholesterol, with MIA
PaCa-2 being responsive by increasing acetyl-CoA avail-
ability for FAS, comparable to that of BxPC-3. After this
metabolic adaptation of MIA PaCa-2 cells to glucose-
derived acetyl-CoA shuttling towards FAS, metformin acts
as an inhibitor of new fatty acid synthesis, while in BxPC-3
metformin dilutes glucose-derived acetate with no apparent
decrease in the rate of new palmitate formation via FAS.
Despite the numerous genetic and phenotypic differences
between BxPC-3 and MIA PaCa-2 cells (Deer et al. 2010),
it is evident that extracellular cholesterol uniformly
decreases 13C labeling for intracellular cholesterol syn-
thesis in both cell lines. Consequently, extracellular cho-
lesterol increases acetyl-CoA shuttling towards FAS from
















































Fig. 5 Metabolic profile changes associated with CHS and MET
treatment in mutant K-ras (MIA PaCa-2) PDAC cell lines. At
baseline, the mutant K-ras cancer cells exhibit less efficient glucose
oxidation and low fatty acid synthase flux with cholesterol readily
synthesized. CHS treatment (green) blocks cholesterol synthesis, by
which glucose-deriving acetyl-CoA is diverted towards fatty acid
synthase, instead of new cholesterol synthesis. This is when addition
of metformin (red) gains a functional fatty acid synthase inhibitory
effect. This demonstrates the contextual System effects of mutated
K-ras, cholesterol and metformin in the metabolic syndrome to inhibit
potentially membrane production and cancer growth. Please note that
hypotheses for further testing are suggested as (1) the effect of CHS
on glut-aminotransferase, (2) further evidence for MET inhibition of
the citrate arm of the TCA cycle and (3) pyruvate carboxylase, which
is only significant in the presence of CHS
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glucose in MIA PaCa-2 cells. The sterol ring is an unre-
cyclable carbon sink when newly synthesized from glucose
derived acetyl-CoA in cells; therefore CHS as an external
supply introduces significant effects in redistributing
acetyl-CoA among cholesterol and fatty acid synthesis
pathways, as shown in our paper. This necessitates the
introduction of 13C tracer-based metabolic flux research
tools in the genetic and signaling research agendas of
human cancers as well as metabolic diseases in order to
better understand the response of whole biological systems
to common drugs.
We acknowledge a potential limitation of this study,
succinate of CHS being a potential substrate for TCA cycle
metabolism. The dose at which CHS was administrated
(1 mM) is 1/25th of that of glucose (4.5 g/glucose/L
(25mM)) in media. We observed no significant decrease in
13CO2D values after CHS treatment, which is an important
assurance that this hemisuccinate did not dilute the TCA
cycle substrate pool to any measurable extent. No such
dilution was expected from cholesterol under any circum-
stance due to its stable C:27 carbon ring that lacks oxida-
tion by mammalian cells.
Another limitation may be that this study did not test
cell membrane synthesis/turnover directly from isolated
membranes for their labeled palmitate pool. We use the
connection between inhibited FAS and limited cell mem-
brane synthesis because undifferentiated cells contain the
majority, over 90 %, of phospho-sphingo- and triglyceride-
derived fatty acids in nuclear and plasma membranes. This
fraction yields most derivatized methyl-palmitate for GC–
MS analyses after saponification of tumor cell pellets.
Previous work with fractionated fat pools of cultured
undifferentiated murine myoblasts (Espinoza et al. 2010)
confirms the assumption that transformed cell use FAS for
new membrane synthesis and proliferation. Palmitate syn-
thesis via FAS for new membrane formation became a
target to treat cancer (Flavin et al. 2010 for review). A
similar mechanism is suggested herein for metformin in the
presence of cholesterol.
Whilst the four measured metabolites and their 13C
isotopomer ratios from glucose generate a highly infor-
mative matrix, they do not describe the full extent of glu-
cose metabolism. Published methods are available for
isotopolome-wide labeling studies with LC-MS (Creek
et al. 2012) and GC-MS (Hiller et al. 2013). Targeted tracer
fate association studies (TTFA or TTFAS) after drug
treatment may provide significantly more information in
the future than do either a non-targeted tracer fate detection
(NTFD) approach or a limited product IWAS. It is
important to point out that even a relatively low but steady
increase in the rate of glucose-derived new acetate can
contribute to enlarged palmitate pools, over time. Even
though there are only a few percent increases in glucose-
derived acetyl-CoA to new palmitate synthesis above that
in control cells, this surrogate marker of newly contributed
acetyl-CoA yields a potentially large new palmitate pool
for membrane synthesis; although the majority, *85 % of
acetyl-CoA are still recycled from existing (unlabeled)
fatty acids, similar to other transformed cell systems (Bu-
lotta et al. 2003). Another important point is that glucose is
a reliable source for new acetyl-CoA synthesis as plasma
concentrations, especially in diabetes, are constantly high.
In the metabolic syndrome this is combined with high
circulating cholesterol, which together yields a reliable
new acetyl-CoA pool (glucose) and an inhibitor of new
cholesterol synthesis (cholesterol) for tumor cells to thrive
with more new palmitate. Metformin limits this new frac-
tion of palmitate synthesis in the context of metabolic
changes in a diabetic host, potentially, based on our
observations.
Using the same principles as genome-wide association
studies (GWAS), this paper demonstrates the effect of
metformin by a targeted isotopolome-wide association
study (IWAS) approach. This is readily expanded towards
system-wide associations (SWAS) when comparing spe-
cific metabolic fingerprints, as well as the effect of Met-
formin in the presence of nutritional factor cholesterol in
obesity, in two genetically diverse tumor cell lines.
Although it may seem ambitious, IWAS presented in a heat
map (EZotopolome) reveals that metformin under high
cholesterol contributes to limit new fatty acid and poten-
tially plasma and nuclear membrane synthesis, demon-
strating a previously unknown mechanism for inhibiting
cancer growth during the metabolic syndrome.
5 Concluding remarks
In conclusion, metformin possesses FAS inhibitory prop-
erties in the context of the combined metabolic effects of
available acetyl-CoA and extracellular cholesterol. Such
contextual synthetic inhibition of FAS by metformin may
partly explain the drug’s demonstrated ability to decelerate
growth in some cancers of the diabetic patient (Li et al.
2009) or patients with metabolic syndrome. One of the
observed side effects, lactic acidosis, is also consistent with
our report that the product of glucose metabolism is lactic
acid when cholesterol and fatty acid new syntheses are
inhibited in the presence of MET.
Acknowledgments We thank F. Tracy Lagunero for metabolite
extraction/processing, Pe´ter Csaba Bı´ro´ for assisting in the cell pro-
liferation studies, Maria Csikos, Ana Geri, Csaba Geri for blinded
spectra processing, Ferenc Na´dudvari for preparing the EZTopolome
visual data review panels and Dale Chenoweth of Austin, Texas, for
co-editing the manuscript. This work was supported by the Hirshberg
Foundation for Pancreatic Cancer Research to EJM, by the National
102 M. J. Cantoria et al.
123
Needs Fellow (NNF) training grant from the USDA [Grant
2010-38420-20369] for MJC, by the UCLA Center for Excellence in
Pancreatic Diseases of the NCI [Grant 1 P01 AT003960-01A1] and
the UCLA Clinical and Translational Science Institute [Grant
UL1TR000124] to LGB.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
Algire, C., Amrein, L., Zakikhani, M., Panasci, L., & Pollak, M.
(2010). Metformin blocks the stimulative effect of a high-energy
diet on colon carcinoma growth in vivo and is associated with
reduced expression of fatty acid synthase. Endocrine Related
Cancer, 17(2), 351–360.
Algire, C., Zakikhani, M., Blouin, M. J., Shuai, J. H., & Pollak, M.
(2008). Metformin attenuates the stimulatory effect of a high-
energy diet on in vivo LLC1 carcinoma growth. Endocrine
Related Cancer, 15(3), 833–839.
Ben Sahra, I., Laurent, K., Giuliano, S., Larbret, F., Ponzio, G.,
Gounon, P., et al. (2010a). Targeting cancer cell metabolism:
The combination of metformin and 2-deoxyglucose induces p53-
dependent apoptosis in prostate cancer cells. Cancer Research,
70(6), 2465–2475.
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-
Brustel, Y., Auberger, P., et al. (2011). Metformin, independent
of AMPK, induces mTOR inhibition and cell-cycle arrest
through REDD1. Cancer Research, 71(13), 4366–4372.
Ben Sahra, I., Tanti, J. F., & Bost, F. (2010b). The combination of
metformin and 2 deoxyglucose inhibits autophagy and induces
AMPK-dependent apoptosis in prostate cancer cells. Autophagy,
6(5). doi:10.1158/0008-5472.CAN-09-2782.
Bhalla, K., Hwang, B. J., Dewi, R. E., Twaddel, W., Goloubeva, O.
G., Wong, K. K., et al. (2012). Metformin prevents liver
tumorigenesis by inhibiting pathways driving hepatic lipogene-
sis. Cancer Prevention Research (Philadelphia), 5(4), 544–552.
Bo, S., Ciccone, G., Rosato, R., Villois, P., Appendino, G., Ghigo, E.,
et al. (2011). Cancer mortality reduction and metformin: A
retrospective cohort study in type 2 diabetic patients. Diabetes
Obesity and Metabolism, 14, 23–29.
Boros, L. G., Brackett, D. J., & Harrigan, G. G. (2003). Metabolic
biomarker and kinase drug target discovery in cancer using
stable isotope-based dynamic metabolic profiling (SIDMAP).
Current Cancer Drug Targets, 3(6), 445–453.
Bowker, S. L., Majumdar, S. R., Veugellers, P., & Johnson, J. A.
(2006). Increased cancer-related mortality for patients with type
2 diabetes who use sulfonylureas or insulin. Diabetes Care, 29,
254–258.
Bulotta, A., Perfetti, R., Hui, H., & Boros, L. G. (2003). GLP-1
stimulates glucose-derived de novo fatty acid synthesis and
chain elongation during cell differentiation and insulin release.
Journal of Lipid Research, 44(8), 1559–1565.
Cheong, J. H., Park, E. S., Liang, J., Dennison, J. B., Tsavachidou, D.,
Nguyen-Charles, C., et al. (2011). Dual inhibition of tumor
energy pathway by 2-deoxyglucose and metformin is effective
against a broad spectrum of preclinical cancer models. Molec-
ular Cancer Therapeutics, 10(12), 2350–2362.
Creek, D. J., Chokkathukalam, A., Jankevics, A., Burgess, K. E.,
Breitling, R., & Barrett, M. P. (2012). Stable isotope-assisted
metabolomics for network-wide metabolic pathway elucidation.
Analytical Chemistry, 84(20), 8442–8447.
da Silva, D., Ausina, P., Alencar, E. M., Coelho, W. S., & Zancan, P.
(2012). Metformin reverses hexokinase and phosphofructokinase
downregulation and intracellular distribution in the heart of
diabetic mice. IUBMB Life. doi:10.1002/iub.1063.
Deer, E. L., Gonzalez-Hernandez, J., Coursen, J. D., Shea, J. E.,
Ngatia, J., Scaife, C. L., et al. (2010). Phenotype and genotype of
pancreatic cancer cell lines. Pancreas, 39(4), 425–435.
del Barco, S., Vazquez-Martin, A., Cufi, S., Oliveras-Ferraros, C.,
Bosch-Barrera, J., Joven, J., et al. (2011). Metformin: Multi-
faceted protection against cancer. Oncotarget, 2, 896–917.
Dykens, J. A., Jamieson, J., Marroquin, L., Nadanaciva, S., Billis, P.
A., & Will, Y. (2008). Biguanide-induced mitochondrial
dysfunction yields increased lactate production and cytotoxicity
of aerobically-poised HepG2 cells and human hepatocytes
in vitro. Toxicology and Applied Pharmacology, 233, 203–210.
Espinoza, D. O., Boros, L. G., Crunkhorn, S., Gami, H., & Patti, M. E.
(2010). Dual modulation of both lipid oxidation and synthesis by
peroxisome proliferator-activated receptor-gamma coactivator-
1alpha and -1beta in cultured myotubes. Federation of American
Societies for Experimental Biology Journal, 24, 1003–1014.
Evans, J. M., Donelly, L. A., Emslie-Smith, A. M., Alessi, D. R., &
Morris, A. D. (2005). Metformin and reduced risk of cancer in
diabetic patients. British Medical Journal, 330, 1304–1305.
Fitzgerald, E., Mathieu, S., & Ball, A. (2009). Metformin associated
lactic acidosis. BMJ, 339, b3660. doi:10.1136/bmj.b3660.
Flavin, R., Peluso, S., Nguyen, P. L., & Loda, M. (2010). Fatty acid
synthase as a potential therapeutic target in cancer. Future
Oncology, 6, 551–562.
Fulgencio, J. P., Kohl, C., Girard, J., & Pegorier, J. P. (2001). Effect
of metformin on fatty acid and glucose metabolism in freshly
isolated hepatocytes and on specific gene expression in cultured
hepatocytes. Biochemical Pharmacology, 62(4), 439–446.
Gonzalez-Barroso, M. M., Anedda, A., Gallardo-Vara, E., Redondo-
Horcajo, M., Rodriguez-Sanchez, L., & Rial, E. (2012). Fatty
acids revert the inhibition of respiration caused by the antidi-
abetic drug metformin to facilitate their mitochondrial beta-
oxidation. Biochimica et Biophysica Acta. doi:10.1016/j.bbabio.
2012.02.019.
Goodwin, J. S., Drake, K. R., Remmert, C. L., & Kenworthy, A. K.
(2005). Ras diffusion is sensitive to plasma membrane viscosity.
Biophysical Journal, 89(2), 1398–1410.
Guigas, B., Bertrand, L., Taleux, N., Foretz, M., Wiernsperger, N.,
Vertommen, D., et al. (2006). 5-aminoimidazole-4-carboxamide-
1-B-D-ribofuranoside and metformin inhibit glucose phosphory-
lation by an AMP-activated protein kinase-independent effect on
glucokinase translocation. Diabetes, 55, 865–874.
Harrigan, G. G., Colca, J., Szalma, S., & Boros, L. G. (2006). PNU-
91325 increases fatty acid synthesis from glucose and mito-
chondrial long chain fatty acid degradation: a comparative
tracer-based metabolomics study with rosiglitazone and pioglit-
azone in HepG2 cells. Metabolomics, 2(1), 21–29.
Harris, D. M., Li, L., Chen, M., Lagunero, F. T., Go, V. L. W., &
Boros, L. G. (2012). Diverse mechanisms of growth inhibition
by luteolin, resveratrol, and quercetin in MIA PaCa-2 cells: A
comparative glucose tracer study with fatty acid synthase
inhibitor C75. Metabolomics, 8, 201–210.
Hiller, K., Wegner, A., Weindl, D., Cordes, T., Metallo, C. M.,
Kelleher, J. K., et al. (2013). NTFD—a stand-alone application
for the non-targeted detection of stable isotope-labeled com-
pounds in GC/MS data. Bioinformatics, 29(9), 1226–1228.
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brule, S., Viollet,
B., et al. (2010). Metformin, independent of AMPK, inhibits
mTORC1 in a rag GTPase-dependent manner. Cell Metabolism,
11(5), 390–401.
Contextual synthetic efficacies: metformin, K-ras 103
123
Kim, E., Liu, N.-C., Yu, I.-C., Lin, H.-Y., Lee, Y.-F., Sparks, J. D.,
et al. (2011). Metformin inhibits nuclear receptor TR4-mediated
hepatic stearoyl-CoA desaturase 1 gene expression with altered
insulin sensitivity. Diabetes, 60, 1493–1503.
Kisfalvi, K., Eibl, G., Sinnett-Smith, J., & Rozengurt, E. (2009).
Metformin disrupts crosstalk between G protein-coupled recep-
tor and insulin receptor signaling systems and inhibits pancreatic
cancer growth. Cancer Research, 69(16), 6539–6545.
Lee, W. N. (1996). Stable isotopes and mass isotopomer study of fatty
acid and cholesterol synthesis a review of the MIDA approach.
Advances in Experimental Medicine and Biology, 399, 95–114.
Lee, W. N., Bergner, E. A., & Guo, Z. K. (1992). Mass isotopomer
pattern and precursor-product relationship. Biological Mass
Spectrometry, 21(2), 114–122.
Lee, W.-N. P., Boros, L. G., Puigjaner, J., Bassilian, S., Lim, S., &
Cascante, M. (1998). Mass isotopomer study of the non-
oxidative pathways of the pentose cycle with [1,2–13C2]glucose.
American Journal of Physiology, 274(5 Pt 1), E843–E851.
Li, D., Yeung, S. C., Hassan, M. M., Konopleva, M., & Abbruzzese,
J. L. (2009). Antidiabetic therapies affect risk of pancreatic
cancer. Gastroenterology, 137(2), 482–488.
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A.
D., & Evans, J. M. (2009). New users of metformin are at low
risk of incident cancer: a cohort study among people with type 2
diabetes. [Research Support, Non-U.S. Gov’t]. Diabetes Care,
32(9), 1620–1625.
Little, J. L., & Kridel, S. J. (2008). Fatty acid synthase activity in
tumor cells. SubCellular Biochemistry, 49, 169–194.
Lopez-Crapez, E., Chypre, C., Saavedra, J., Marchand, J., & Grenier,
J. (1997). Rapid and large-scale method to detect K-ras gene
mutations in tumor samples. Clinical Chemistry, 43(6 Pt 1),
936–942.
Menendez, J. A., & Lupu, R. (2007). Fatty acid synthase and the
lipogenic phenotype in cancer pathogenesis. Nature Reviews
Cancer, 7(10), 763–777.
Menendez, J. A., Oliveras-Ferraros, C., Cufi, S., Corominas-Faja, B.,
Joven, J., Martin-Castillo, B., et al. (2012). Metformin is
synthetically lethal with glucose withdrawal in cancer cells.
Cell Cycle, 11(15), 2782–2792.
Metallo, C. M., Walther, J. L., & Stephanopoulos, G. (2009).
Evaluation of 13C isotopic tracers for metabolic flux analysis in
mammalian cells. Journal of Biotechnology, 144(3), 167–174.
Meuillet, E. J., Leray, V., Hubert, P., Leray, C., & Cremel, G.
(1999a). Incorporation of exogenous lipids modulates insulin
signaling in the hepatoma cell line, HepG2. Biochimica et
Biophysica Acta, 1454(1), 38–48.
Meuillet, E. J., Wiernsperger, N., Mania-Farnell, B., Hubert, P., &
Cremel, G. (1999b). Metformin modulates insulin receptor
signaling in normal and cholesterol-treated human hepatoma
cells (HepG2). [Research Support, Non-U.S. Gov’t]. European
Journal of Pharmacology, 377(2–3), 241–252.
Mihaylova, M. M., & Shaw, R. J. (2011). The AMPK signalling
pathway coordinates cell growth, autophagy and metabolism.
Nature Cell Biology, 13(9), 1016–1023.
Monami, M., Colombi, C., Balzi, D., Dicembrini, I., Giannini, S.,
Melani, C., et al. (2011). Metformin and cancer occurrence in
insulin-treated type 2 diabetic patients. Diabetes Care, 34,
129–131.
Pollak, M. (2012). Metformin and pancreatic cancer: A clue requiring
investigation. Clinical Cancer Research, 18(10), 2723–2725.
Preiss, D. J., & Sattar, N. (2009). Metformin and lactic acidosis.
Metformin: Framed again? British Medical Journal, 23, 339.
Ruiter, R., Visser, L. E., van Herk-Sukel, M. P. P., Coebergh, J.-W.
W., Haal, H. R., Geelhoed-Duijvestijn, P. H., et al. (2012).
Lower risk of cancer in patients on metformin in comparison
with those on sulfonylurea derivatives. Diabetes Care, 35,
119–124.
Sadeghi, N., Abbruzzese, J. L., Yeung, S. C., Hassan, M., & Li, D.
(2012). Metformin use is associated with better survival of
diabetic patients with pancreatic cancer. Clinical Cancer
Research, 18(10), 2905–2912.
Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., &
Sabatini, D. M. (2010). Ragulator-Rag complex targets
mTORC1 to the lysosomal surface and is necessary for its
activation by amino acids. Cell, 141(2), 290–303.
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen,
C. C., Bar-Peled, L., et al. (2008). The Rag GTPases bind raptor
and mediate amino acid signaling to mTORC1. Science,
320(5882), 1496–1501.
Sandulache, V. C., Ow, T. J., Pickering, C. R., Frederick, M. J., Zhou,
G., Fokt, I., et al. (2011). Glucose, not glutamine, is the dominant
energy source required for proliferation and survival of head and
neck squamous carcinoma cells. Cancer, 117(13), 2926–2938.
Viollet, B., Guigas, B., Sans Garcia, N., Leclerc, J., Foretz, M., &
Adreelli, F. (2012). Cellular and molecular mechanisms of
metformin: An overview. Clinical Science, 122, 253–270.
Vizan, P., Boros, L. G., Figueras, A., Capella, G., Mangues, R.,
Bassilian, S., et al. (2005). K-ras codon-specific mutations
produce distinctive metabolic phenotypes in NIH3T3 mice
[corrected] fibroblasts. Cancer Research, 65(13), 5512–5515.
Wakil, S. J., & Abu-Elheiga, L. A. (2009). Fatty acid metabolism:
Target for metabolic syndrome. Journal of Lipid Research,
50(Suppl), S138–S143.
Walter, K., Hong, S. M., Nyhan, S., Canto, M., Fedarko, N., Klein, A.,
et al. (2009). Serum fatty acid synthase as a marker of pancreatic
neoplasia. Cancer Epidemiol Biomarkers Prev, 18(9), 2380–
2385.
Whitaker-Menezes, D., Martinez-Outschoorn, U. E., Flomenberg, N.,
Birbe, R. C., Witkiewicz, A. K., Howell, A., et al. (2011).
Hyperactivation of oxidative mitochondrial metabolism in
epithelial cancer cells in situ: Visualizing the therapeutic effects
of metformin in tumor tissue. Cell Cycle, 10(23), 4047–4064.
Wiernsperger, N., & Rapin, J. R. (1995). Metformin-insulin interac-
tions: From organ to cell. Diabetes/Metabolism Reviews,
11(Suppl 1), S3–12.
104 M. J. Cantoria et al.
123
